Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and Lidocaine for Surgery-Induced BBB Disruption in Elderly
NCT06090955Recruiting
- Sponsor
- Samsung Medical Center
- Start
- Oct 2023
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dexmedetomidine and Lidocaine Hydrochloride Injection, without epinephrine in postoperative delirium (POD) (3 arms), sponsored by Samsung Medical Center. Primary endpoint: Cerebrospinal-plasma albumin ratio. Started Oct 2023; status: recruiting.
02
Drugs
dexmedetomidineLidocaine Hydrochloride Injection, without epinephrine
03
Conditions
postoperative delirium (POD)
Beyond the preview
Go deeper on NCT06090955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06090955.